A new study, led by radiation oncology physicists at Miami Cancer Institute, part of Baptist Health South Florida, displayed positive results using intracranial stereotactic radiosurgery, also known as SRS, for an MR-guided radiotherapy system.

The study, ‘Commissioning Intracranial Stereotactic Radiosurgery (SRS) for an MR-guided Radiotherapy (MRgRT) system: MR-RT Localisation and Dosimetric End-to-End Validation’ published in the International Journal of Radiation Oncology - Biology - Physics (IJROBP), highlights positive accuracy through an end-to-end hidden target test to quantify the imaging, planning, and delivery coincidence of an MR Linac system, ViewRay MRIdian.

Kathryn Mittauer, Ph.D., lead physicist for the MR-guided radiation therapy program with Miami Cancer Institute, was the first author of this study.

Mittauer explains the team developed an in-house MR head phantom to simulate stereotactic radiosurgery for brain tumours.

Specifically, the study simulated intracranial spherical targets, an irregularly shaped target, and a target abutting the brainstem.  

Nema Bassiri, Ph.D., radiation oncology physicist with Miami Cancer Institute, and senior author of this study, explains that this delivery was successful with up to 99% accuracy.

Bassiri adds that “this work enables the utilisation of novel MR-guided radiotherapy technology for intracranial SRS, which has not been used with MR Linac systems.”

MRI is the gold standard for evaluating and localise brain tumours due to soft tissue visualisation capabilities.

“Since we demonstrated the accuracy of ViewRay MRIdian’s capability to deliver within a 1 mm setup margin in this work, we have now deployed this novel technique to our brain cancer patients at Miami Cancer Institute”, adds Mittauer.

The team has observed that the volume of a patient’s tumour change during a 3-fraction radiosurgery course through using the onboard MR image guidance of the MR Linac system.

“What’s most impressive is that we are able to visualise how the tumour volume changes day to day, even throughout a short 3-fraction treatment. This research will help us better understand how these tumours change (including tumour progression), and the role of adaptive radiotherapy which adjusts the radiation to account for these changes to enable more precision”, shared Mittauer.

“In the field of radiation oncology, this is revolutionary as we assess the frequency of these anatomical changes and how this will inform us for even other radiation choices.”

“In the future, we will see more studies that investigate the benefit of using MRIdian for stereotactic radiosurgery. This study will help advance the community by providing a blueprint to implement MR-guided SRS program for anyone who is interested in utilising this treatment technique”, shared Bassiri.

Source: Baptist Health South Florida